Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maridebart Cafraglutide in Type 2 Diabetes Mellitus
NCT07160257Phase 1Active, not recruiting
- Sponsor
- Amgen
- Start
- Aug 2025
- Primary completion
- Nov 2026
- Modality
- Peptides, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Maridebart cafraglutide with Placebo (2 arms). Primary endpoint: Change from Baseline in M-value from Hyperinsulinemic-euglycemic Clamp at 25 weeks. Started Aug 2025; status: active, not recruiting.
02
Drugs
maridebart cafraglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07160257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07160257.